Similar articles for PMID: 24715137

Year	Number of Results
1988	1
1989	1
1993	1
1994	3
1995	2
1996	3
1997	1
1999	2
2000	2
2001	2
2002	1
2003	3
2004	2
2005	1
2006	3
2007	5
2008	12
2009	8
2010	9
2011	5
2012	6
2013	4
2014	9
2015	4
2016	2
2017	3
2019	3
2021	0

1

Lesson of the month (1): cabergoline - 'i eat funny on that'.

Premaratne VS, Saeger I, Macdonald BK. Premaratne VS, et al. Clin Med (Lond). 2014 Apr;14(2):205-7. doi: 10.7861/clinmedicine.14-2-205. Clin Med (Lond). 2014. PMID: 24715137 Free PMC article.

2

A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.

Löndahl M, Nilsson A, Lindgren H, Katzman P. Löndahl M, et al. Eur J Endocrinol. 2008 Apr;158(4):583-5. doi: 10.1530/EJE-07-0584. Eur J Endocrinol. 2008. PMID: 18362307

3

Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.

Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E. Bogazzi F, et al. Int J Clin Pract. 2008 Dec;62(12):1864-9. doi: 10.1111/j.1742-1241.2008.01779.x. Epub 2008 May 6. Int J Clin Pract. 2008. PMID: 18462372

4

AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.

Samson SL, Ezzat S. Samson SL, et al. Endocr Pract. 2014 Jun;20(6):608-16. doi: 10.4158/EP14148.RA. Endocr Pract. 2014. PMID: 24969114

5

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

Rains CP, Bryson HM, Fitton A. Rains CP, et al. Drugs. 1995 Feb;49(2):255-79. doi: 10.2165/00003495-199549020-00009. Drugs. 1995. PMID: 7729332 Review.

6

Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.

Barake M, Evins AE, Stoeckel L, Pachas GN, Nachtigall LB, Miller KK, Biller BM, Tritos NA, Klibanski A. Barake M, et al. Pituitary. 2014 Apr;17(2):150-6. doi: 10.1007/s11102-013-0480-6. Pituitary. 2014. PMID: 23504371 Free PMC article.

7

Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.

Coronas R, Cobo J, Giménez-Palop O, Ortega E, Márquez M. Coronas R, et al. Curr Drug Saf. 2012 Apr;7(2):92-8. doi: 10.2174/157488612802715753. Curr Drug Saf. 2012. PMID: 22873493

8

[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].

Steffensen C, Mægbæk ML, Laurberg P, Andersen M, Kistorp C, Nørrelund H, Dal J, Jørgensen JO. Steffensen C, et al. Ugeskr Laeger. 2014 Jan 6;176(1):58-60. Ugeskr Laeger. 2014. PMID: 24629610 Review. Danish.

9

Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine.

[No authors listed] [No authors listed] Prescrire Int. 2000 Feb;9(45):195-7. Prescrire Int. 2000. PMID: 11503793

10

Cabergoline and mitral regurgitation.

Delgrange E. Delgrange E. N Engl J Med. 2006 Jan 26;354(4):420; author reply 420. doi: 10.1056/NEJMc053329. N Engl J Med. 2006. PMID: 16436779 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed